Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
131I-MIBG in Resistant Neuroblastoma or Malignant Chromaffin Cell Tumors
NCT00107289Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2006
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Iobenguane I-131 in neuroblastoma, pheochromocytoma and Paraganglioma (PGL), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Objective Response Rate at 2 years. Started May 2006; status: recruiting.
02
Drugs
Iobenguane I-131
03
Conditions
neuroblastomapheochromocytomaParaganglioma (PGL)
Beyond the preview
Go deeper on NCT00107289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00107289.